Purdue Pharma

Latest news

• FDA Approves Hysingla ER - Extended-Release Hydrocodone with Abuse-Deterrent Properties
  20 November 2014
• FDA Approves Targiniq ER Extended-Release Oxycodone with Abuse-Deterrent Properties
  23 July 2014
• FDA Accepts for Review Purdue Pharma’s New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCL Controlled-Release) Tablets CII
  26 November 2013
• FDA Approves Intermezzo for Middle-of-the-Night Waking Followed by Difficulty Returning to Sleep
  23 November 2011
• Transcept Pharmaceuticals Announces Intermezzo PDUFA Action Date of November 27, 2011
  7 October 2011
• Transcept Pharmaceuticals Announces Plan to Resubmit Intermezzo New Drug Application Following Meeting with the U.S. Food & Drug Administration
  14 September 2011
• Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo New Drug Application
  15 July 2011
• Transcept Pharmaceuticals Expects Complete Response Letter on Intermezzo New Drug Application Based on Teleconference with FDA
  13 July 2011
• Transcept Pharmaceuticals Resubmits Intermezzo New Drug Application for the Treatment of Middle of the Night Awakenings
  19 January 2011
• Transcept Pharmaceuticals Updates Plan for Intermezzo NDA Resubmission Following Teleconference With the FDA
  25 March 2010

Drugs Associated with Purdue Pharma LP

Purdue Pharma LP manufactures, markets and/or distributes more than 12 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.